Should You Buy Progyny Inc (PGNY) Today? Analysis, Price Targets, and 2026 Outlook.
No data
Options Data
No data
Growth
Profitability
Efficiency
Wall Street analysts forecast PGNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PGNY is 29.75 USD with a low forecast of 26 USD and a high forecast of 34 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast PGNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PGNY is 29.75 USD with a low forecast of 26 USD and a high forecast of 34 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 24.120
Low
26
Averages
29.75
High
34
Current: 24.120
Low
26
Averages
29.75
High
34
BTIG
Buy
maintain
$30 -> $35
AI Analysis
2026-01-21
Reason
BTIG
Price Target
$30 -> $35
AI Analysis
2026-01-21
maintain
Buy
Reason
BTIG raised the firm's price target on Progyny to $35 from $30 and keeps a Buy rating on the shares following the JP Morgan Healthcare Conference. The company sees Q4 revenue, net income, and adjusted EBITDA to be slightly above previous guidance due to member engagement tracking favorably relative to expectations, the analyst tells investors in a research note. Demand, new client wins, and member adds are all good, and Progyny continues to build on its industry-leading position within fertility and family building, the firm added.
Citizens
Constantine Davides
Market Perform -> Outperform
upgrade
$30
2026-01-20
Reason
Citizens
Constantine Davides
Price Target
$30
2026-01-20
upgrade
Market Perform -> Outperform
Reason
Citizens analyst Constantine Davides upgraded Progyny to Outperform from Market Perform with a $30 price target. The firm says a meeting with management increased its conviction in the company's "moat, retention rates, and new solution potential." At current valuation levels, Citizens sees an "asymmetric" risk/reward opportunity. Progyny's large client loss has proven to be an isolated event while its new products are starting their ramp. the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PGNY
